Key result
Vericiguat reduces CV death or HF hospitalization vs placebo in high-risk patients.
Why the study?
Does vericiguat reduce the incidence of death from cardiovascular causes or hospitalization for heart failure in patients with high-risk heart failure and reduced ejection fraction?
Does vericiguat reduce the incidence of death from cardiovascular causes or hospitalization for heart failure in patients with high-risk heart failure and reduced ejection fraction?
Vericiguat reduces the composite of cardiovascular death or heart failure hospitalization in patients with high-risk heart failure and reduced ejection fraction compared to placebo.
Answers are grounded in this paper and cite their sources.
Supports vericiguat addition in high-risk HFrEF; confirms benefit of sGC stimulation on top of GDMT.
Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo. (Funded by Merck Sharp & Dohme [a subsidiary of Merck] and Bayer; VICTORIA ClinicalTrials.gov number, NCT02861534.).
No takes yet. Share an insight, caveat, or question.
Armstrong et al. (2020) studied this question. Vericiguat reduced the incidence of cardiovascular death or heart failure hospitalization among high-risk patients compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: